GoodRx director awarded 4,642 deferred stock units
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant and updated holdings in Class A common stock. On May 27, 2026, he received 4,642 deferred stock units at a price of $0.00 per share, bringing his directly held shares to 247,502.
The deferred stock units vest as to 2% of the underlying shares on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months. The units will settle in shares on the earliest of December 31, 2029, Separation from Service, a Change in Control, death, or Disability under the company’s Deferred Compensation Plan for Directors.
The filing also lists indirect holdings through several grantor retained annuity trusts and a spouse account. Hirsch disclaims pecuniary interest, voting, or investment control over shares held by the CH 2024-2 GRAT and CH 2025 GRAT established for his spouse.
Insider Trade Summary
Grant/Award: 4,642 shares
Grant/Award
6 txns
Insider
Hirsch Douglas Joseph
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 4,642 | $0.00 | $0.00 |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Class A Common Stock — 247,502 shares (Direct);
Class A Common Stock — 543,377 shares (Indirect, By DH 2024-2 GRAT);
Class A Common Stock — 2,089,343 shares (Indirect, By DH 2025 GRAT);
Class A Common Stock — 1 shares (Indirect, By Spouse);
Class A Common Stock — 543,377 shares (Indirect, By CH 2024-2 GRAT);
Class A Common Stock — 2,089,343 shares (Indirect, By CH 2025 GRAT)
Footnotes (5)
- F1. Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock. The deferred stock units will vest as to 2% of the underlying shares on May 31, 2026, and the remining 98% will vest in substantially equal monthly installments on last day of each month over the following 7 months, subject to continued service through the applicable vesting date. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors).
- F2. Share held directly by DH 2024 -2 GRAT, a grantor retained annuity trust (the "DH 2024-2 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the DH 2024-2 GRAT.
- F3. Share held directly by DH 2025 GRAT, a grantor retained annuity trust (the "DH 2025 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the DH 2025 GRAT.
- F4. Share held directly by CH 2024-2 GRAT, a grantor retained annuity trust (the "CH 2024-2 GRAT"). Chona Hirsch, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the CH 2024-2 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the CH 2024-2 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares.
- F5. Share held directly by CH 2025 GRAT, a grantor retained annuity trust (the "CH 2025 GRAT"). Chona Hirsch, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the CH 2025GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the CH 2025 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares.
Key Figures
Deferred stock units granted: 4,642 units
Direct shares after grant: 247,502 shares
Initial vesting portion: 2%
+4 more
7 metrics
Deferred stock units granted
4,642 units
Class A common stock award on May 27, 2026 at $0.00
Direct shares after grant
247,502 shares
Class A common stock held directly following the transaction
Initial vesting portion
2%
Vests on May 31, 2026 of the deferred stock units
Remaining vesting portion
98%
Vests in equal monthly installments over the next 7 months
Settlement latest date
December 31, 2029
Latest settlement date for deferred stock units under plan
DH 2025 GRAT holding
2,089,343 shares
Indirect Class A common stock position via DH 2025 GRAT
DH 2024-2 GRAT holding
543,377 shares
Indirect Class A common stock position via DH 2024-2 GRAT
Key Terms
deferred stock units, grantor retained annuity trust, Separation from Service, Change in Control, +1 more
5 terms
deferred stock units financial
"Reflects deferred stock units. Each deferred stock unit represents a contingent right to receive one share of Class A common stock."
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
grantor retained annuity trust financial
"Share held directly by DH 2024 -2 GRAT, a grantor retained annuity trust (the "DH 2024-2 GRAT")."
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
Separation from Service financial
"The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control;"
Change in Control financial
"The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control;"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Deferred Compensation Plan for Directors financial
"each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors"
A deferred compensation plan for directors is an arrangement that lets board members postpone receiving part of their pay until a later date—often retirement or a set future time—so the money can grow or be paid under specified conditions. Think of it like directing a portion of your paycheck into a locked savings account that pays out later; investors care because it creates future cash or stock obligations, signals how the company motivates and retains leadership, and can affect shareholder value through timing of payouts or potential dilution.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GoodRx (GDRX) director Douglas Hirsch report in this Form 4?
Douglas Hirsch reported receiving 4,642 deferred stock units of GoodRx Class A common stock as director compensation. The filing also updates his direct and indirect share holdings, including positions held through several grantor retained annuity trusts and an account associated with his spouse.
What are the vesting terms of Douglas Hirsch’s 4,642 deferred stock units at GoodRx (GDRX)?
The 4,642 deferred stock units vest 2% of the underlying shares on May 31, 2026. The remaining 98% vest in substantially equal monthly installments on the last day of each month over the next seven months, conditioned on his continued service through each applicable vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates